These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34769168)

  • 21. Renal cystic disease in the Fbn1
    Hibender S; Wanga S; van der Made I; Vos M; Mulder BJ; Balm R; de Vries CJ; de Waard V
    Cardiovasc Pathol; 2019; 38():1-6. PubMed ID: 30359839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anatomically specific reactive oxygen species production participates in Marfan syndrome aneurysm formation.
    Emrich F; Penov K; Arakawa M; Dhablania N; Burdon G; Pedroza AJ; Koyano TK; Kim YM; Raaz U; Connolly AJ; Iosef C; Fischbein MP
    J Cell Mol Med; 2019 Oct; 23(10):7000-7009. PubMed ID: 31402541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of HIPK2 Alleviates Thoracic Aortic Disease in Mice With Progressively Severe Marfan Syndrome.
    Caescu CI; Hansen J; Crockett B; Xiao W; Arnaud P; Spronck B; Weinberg A; Hashimoto T; Murtada SI; Borkar R; Gallo JM; Jondeau G; Boileau C; Humphrey JD; He JC; Iyengar R; Ramirez F
    Arterioscler Thromb Vasc Biol; 2021 Sep; 41(9):2483-2493. PubMed ID: 34320838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of TGFBR1 and TGFBR2 genetic variants in Marfan syndrome.
    De Cario R; Sticchi E; Lucarini L; Attanasio M; Nistri S; Marcucci R; Pepe G; Giusti B
    J Vasc Surg; 2018 Jul; 68(1):225-233.e5. PubMed ID: 28847661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extracellular Tuning of Mitochondrial Respiration Leads to Aortic Aneurysm.
    Oller J; Gabandé-Rodríguez E; Ruiz-Rodríguez MJ; Desdín-Micó G; Aranda JF; Rodrigues-Diez R; Ballesteros-Martínez C; Blanco EM; Roldan-Montero R; Acuña P; Forteza Gil A; Martín-López CE; Nistal JF; Lino Cardenas CL; Lindsay ME; Martín-Ventura JL; Briones AM; Redondo JM; Mittelbrunn M
    Circulation; 2021 May; 143(21):2091-2109. PubMed ID: 33709773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerated Marfan syndrome model recapitulates established signaling pathways.
    Gensicke NM; Cavanaugh NB; Andersen ND; Huang T; Qian L; Dyle MC; Turek JW
    J Thorac Cardiovasc Surg; 2020 May; 159(5):1719-1726. PubMed ID: 31272746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement C3a/C3aR inhibition alleviates the formation of aortic aneurysm in Marfan syndrome mice.
    Zhang F; Yao K; Liu Y; Zhou M; Zhang Y; Hong S; Wu J; Zhang C
    BMC Cardiovasc Disord; 2024 Aug; 24(1):417. PubMed ID: 39127656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting feed-forward signaling of TGFβ/NOX4/DHFR/eNOS uncoupling/TGFβ axis with anti-TGFβ and folic acid attenuates formation of aortic aneurysms: Novel mechanisms and therapeutics.
    Huang K; Wang Y; Siu KL; Zhang Y; Cai H
    Redox Biol; 2021 Jan; 38():101757. PubMed ID: 33126053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes.
    Takeda N; Yagi H; Hara H; Fujiwara T; Fujita D; Nawata K; Inuzuka R; Taniguchi Y; Harada M; Toko H; Akazawa H; Komuro I
    Int Heart J; 2016 May; 57(3):271-7. PubMed ID: 27181042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.
    Hibender S; Franken R; van Roomen C; Ter Braake A; van der Made I; Schermer EE; Gunst Q; van den Hoff MJ; Lutgens E; Pinto YM; Groenink M; Zwinderman AH; Mulder BJ; de Vries CJ; de Waard V
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1618-26. PubMed ID: 27283746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrative systems approach identifies novel candidates in Marfan syndrome-related pathophysiology.
    Bhushan R; Altinbas L; Jäger M; Zaradzki M; Lehmann D; Timmermann B; Clayton NP; Zhu Y; Kallenbach K; Kararigas G; Robinson PN
    J Cell Mol Med; 2019 Apr; 23(4):2526-2535. PubMed ID: 30677223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Redox stress in Marfan syndrome: Dissecting the role of the NADPH oxidase NOX4 in aortic aneurysm.
    Jiménez-Altayó F; Meirelles T; Crosas-Molist E; Sorolla MA; Del Blanco DG; López-Luque J; Mas-Stachurska A; Siegert AM; Bonorino F; Barberà L; García C; Condom E; Sitges M; Rodríguez-Pascual F; Laurindo F; Schröder K; Ros J; Fabregat I; Egea G
    Free Radic Biol Med; 2018 Apr; 118():44-58. PubMed ID: 29471108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Notch3 Activation on Aortic Aneurysm Development in Marfan Syndrome.
    Jespersen K; Li C; Batra R; Stephenson CA; Harding P; Sestak K; Foley RT; Greene H; Meisinger T; Cook JR; Baxter BT; Xiong W
    J Immunol Res; 2022; 2022():7538649. PubMed ID: 35211631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.
    Fisch S; Bachner-Hinenzon N; Ertracht O; Guo L; Arad Y; Ben-Zvi D; Liao R; Schneiderman J
    J Am Heart Assoc; 2020 May; 9(10):e014761. PubMed ID: 32378446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice.
    Park JH; Kim MS; Ham S; Park ES; Kim KL; Suh W
    Biomol Ther (Seoul); 2020 Jan; 28(1):98-103. PubMed ID: 31284709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.
    Yang HH; Kim JM; Chum E; van Breemen C; Chung AW
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):305-312.e2. PubMed ID: 20189193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome.
    Chung AW; Au Yeung K; Cortes SF; Sandor GG; Judge DP; Dietz HC; van Breemen C
    Br J Pharmacol; 2007 Apr; 150(8):1075-83. PubMed ID: 17339838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Murine Model of Marfan Syndrome Accelerates Aortopathy and Cardiomyopathy.
    Cavanaugh NB; Qian L; Westergaard NM; Kutschke WJ; Born EJ; Turek JW
    Ann Thorac Surg; 2017 Aug; 104(2):657-665. PubMed ID: 28347539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thoracic aortic disease in two patients with juvenile polyposis syndrome and SMAD4 mutations.
    Teekakirikul P; Milewicz DM; Miller DT; Lacro RV; Regalado ES; Rosales AM; Ryan DP; Toler TL; Lin AE
    Am J Med Genet A; 2013 Jan; 161A(1):185-91. PubMed ID: 23239472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.